Liver cell protection

Liver cell protection" is a process, not a molecular target. It refers to a diverse range of molecular pathways, genes, and cell types that protect the liver against injury, promote regeneration, or mediate repair. This includes modulation of apoptosis, antioxidants, immune cell activity, and cellular pathways controlling proliferation and fibrosis. Molecules such as microRNAs, transcription factors (e.g., STAT3, Nrf2), receptors (e.g., FXR), cytokines, and cell types (e.g., hepatocytes, Kupffer cells, hepatic stellate cells, natural killer cells) are individually studied as mediators or targets within this broad framework of "liver cell protection". Drugs and biological agents aiming to achieve "liver cell protection" typically modulate these specific downstream entities. The term is often used as a therapeutic goal, not a target. Valid molecular targets involved in liver cell protection include: Farnesoid X receptor (FXR); Nuclear factor erythroid 2–related factor 2 (Nrf2); MicroRNAs (e.g., miR-21, miR-194, miR-125a, miR-182-5p); Transforming growth factor beta (TGF-β); Apoptosis regulators: BCL2, STAT3, JUN. Drugs and interventions for liver cell protection act by targeting these molecules and pathways, for example: Anti-fibrotic agents (targeting TGF-β, hedgehog pathway, or HSCs); Antioxidants (targeting oxidative stress, e.g., mitoquinone, Nrf2 activators); Small interfering RNA (siRNA) or miRNA therapies. Because "Liver cell protection" is a therapeutic objective rather than a druggable entity, all fields specific to individual molecular targets (name, abbreviation, drug interaction, mechanism) are not applicable. In summary, "Liver cell protection" is conceptually and functionally important, but it is not a valid entry for a molecular target database and should be replaced with specific gene/protein/receptor names where possible.